188 related articles for article (PubMed ID: 15088127)
1. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H
Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127
[TBL] [Abstract][Full Text] [Related]
2. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.
Donskov F; Bennedsgaard KM; Von Der Maase H; Marcussen N; Fisker R; Jensen JJ; Naredi P; Hokland M
Br J Cancer; 2002 Jul; 87(2):194-201. PubMed ID: 12107842
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood neutrophils as independent immunologic predictor of response and long-term survival upon immunotherapy in metastatic renal-cell carcinoma.
Atzpodien J; Reitz M
Cancer Biother Radiopharm; 2008 Feb; 23(1):129-34. PubMed ID: 18298337
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
5. Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trial.
Donskov F; Hokland M; Marcussen N; Torp Madsen HH; von der Maase H
Br J Cancer; 2006 Jan; 94(2):218-26. PubMed ID: 16434984
[TBL] [Abstract][Full Text] [Related]
6. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract][Full Text] [Related]
7. Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride.
Jørkov AS; Donskov F; Steiniche T; Ternesten-Bratel A; Naredi P; Hellstrand K; Hokland M
Anticancer Res; 2003; 23(1B):537-42. PubMed ID: 12680142
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response.
Bukowski RM; Olencki T; Wang Q; Peereboom D; Budd GT; Elson P; Sandstrom K; Tuason L; Rayman P; Tubbs R; McLain D; Klein E; Novick A; Finke J
J Immunother; 1997 Jul; 20(4):301-11. PubMed ID: 9220320
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.
Belldegrun A; Pierce W; Kaboo R; Tso CL; Shau H; Turcillo P; Moldawer N; Golub S; deKernion J; Figlin R
J Urol; 1993 Nov; 150(5 Pt 1):1384-90. PubMed ID: 8411405
[TBL] [Abstract][Full Text] [Related]
10. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
[TBL] [Abstract][Full Text] [Related]
11. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2.
Moltó L; Carballido J; Manzano L; Martinez-Martin B; Esquivel F; Chafer J; Olivier C; Alvarez-Mon M
J Immunother; 1999 May; 22(3):260-7. PubMed ID: 10335486
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
[TBL] [Abstract][Full Text] [Related]
13. Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).
Merad M; Angevin E; Wolfers J; Flament C; Lorenzi I; Triebel F; Escudier B; Zitvogel L
J Immunother; 2000; 23(3):369-78. PubMed ID: 10838666
[TBL] [Abstract][Full Text] [Related]
14. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
[TBL] [Abstract][Full Text] [Related]
15. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
16. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic options in the management of renal cell carcinoma.
Glaspy JA
Semin Oncol; 2002 Jun; 29(3 Suppl 7):41-6. PubMed ID: 12068388
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
